103.95 USD
↗ 0.53 (0.51%)PRE MARKET (AS OF 07:11 AM EDT)
Spyre Therapeutics, Inc. Common Stock
SYRENASDAQ • USD
Market: OPEN
Shares of Spyre Therapeutics, Inc. Common Stock (SYRE) are trading at $103.95. The technical outlook is "Buy" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Aug 6, 2026.
Open?$105.00
High?$106.45
Low?$101.06
Prev. Close?$103.42
Volume?1.2K
Avg. Volume?1.3M
VWAP?$103.65
Rel. Volume?0.00x
Bid / Ask
Bid?$86.00 × 100
Ask?$121.98 × 100
Spread?$35.98
Midpoint?$103.99
Valuation & Ratios
Market Cap?9.1B
Shares Out?87.9M
Float?75.4M
Float %?86.8%
P/E Ratio?N/A
P/B Ratio?8.28
EPS?-$1.70
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Address
221 CRESCENT STREET
WALTHAM, MA 02453
Phone: (617) 651-5940
WALTHAM, MA 02453
Phone: (617) 651-5940
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?50
Piotroski F-Score?0/9Weak
Altman Z-Score?75.04Safe
Confidence?49%Low
Short InterestHigh
Short % of Float?16.60%High
Short Interest?12.5M
Days to Cover?9.0
Free Float75.4M
Avg Daily Volume1.4M
Settlement Date2026-07-15
Financial Health
Current Ratio?18.53Strong
Quick Ratio?18.53Strong
Cash Ratio?2.56Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?8.28HIGH▾
Peers100
S&P23
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-33.0CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-13.6%WEAK▾
S&P9
ROA?-12.8%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$9.0B
Fundamentals ratios updated end of day